<DOC>
	<DOCNO>NCT01715129</DOCNO>
	<brief_summary>Assess efficacy safety Triptorelin pamoate 3M formulation ( 11.25mg ) administer subcutaneous route .</brief_summary>
	<brief_title>Induction Maintenance Castration After Subcutaneous Injections Triptorelin Pamoate Patients With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<criteria>Histologically prove locally advanced metastatic prostate cancer suitable androgen deprivation therapy Male age ≥18 year old Screening testosterone level &gt; 125 ng/dL Life expectancy great 12 month judgement Investigator Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Willing give sign informed consent freely Able adhere study visit schedule protocol requirement . Prior hormonal therapy prostate cancer Prior surgery radiotherapy prostate cancer curative intent unless disease verify rise prostate specific antigen ( PSA ) concentration follow ( elevate PSA value last two test conduct least month apart ) patient eligible androgen deprivation therapy Presence history malignancy except non melanoma skin cancer adequately treat least 2 year study entry Painful local bone lesion spinal lesion may lead compression History myocardial infarction , percutaneous coronary intervention , acute coronary syndrome , coronary artery bypass graft , Class III/IV congestive heart failure , cerebrovascular accident , transient ischaemic attack , limb claudication rest , within six month prior start study treatment ongoing symptomatic dysrhythmias , unstable angina , uncontrolled hypertension , untreated atrial uncontrolled ventricular arrhythmia Any condition opinion Investigator , include active latent infection , medical psychiatric condition , presence laboratory abnormality , could confound ability interpret data study , compromise objective study place patient unacceptable risk participates study Abnormal haematological , hepatic renal function : Haemoglobin &lt; 9 g/dL , absolute neutrophil count ≤1.5 x 10^9/L platelet ≤100 x 10^9/L Serum creatinine ≥1.5 time upper limit normal ( ULN ) Aspartate aminotransferase alanine aminotransferase &gt; 2.5 time ULN Known hypersensitivity study treatment , excipients Known active use recreational drug alcohol dependence opinion Investigator Any current use use within six month prior start treatment , medication know affect metabolism and/or secretion androgenic hormone : e.g . ketoconazole , aminoglutethimide , oestrogen , progesterone Use systemic corticosteroid ( inhaled corticosteroid topical application corticosteroid permit ) Aged ≥90 year main study ≥80 year include pharmacokinetic ( PK ) patient population Participation study receipt investigational compound 30 day ( five time elimination half life longer ) prior study entry Any skin condition may preclude s.c. injection administration Known brain epidural metastasis .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>